新型冠状病毒肺炎患者肝损伤机制研究进展*

doi:10.3969/j.issn.1672-5069.2022.03.038

Abstract

Abstract: Objective The pandemic of COVID-19 has ravaged all over the world. The respiratory tract is considered to be the main target of SARS-CoV-2 infection.Some COVID-19 patients have different degrees of liver injuries. We reviewed the progress on mechanism of liver injuries, so as to provide a therapeutic strategies for COVID-19 patients with liver injuries.

Key words: Corona virus disease 2019, Severe acute respiratory syndrome corona virus 2, Liver injury, Cytokine storm

Hu Lingxi, Cui Po, Wang Rongqi. Liver injuries in patients with corona virus disease 2019[J]. Journal of Practical Hepatology, 2022, 25(3): 453-456.

References

[1] 中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第八版). 中华临床感染病杂志,2020,13(5):321-328.
[2] Xin S, Xu J, Yu Y. Abnormal liver function tests of patients with coronavirus disease 2019 in mainland China:A systematic review and Meta-analysis. J Gastrointest Liver Dis,2020,29(2):219-226.
[3] Puelles VG, Lütgehetmann M, Lindenmeyer MT, et al. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med,2020,383(6):590-592.
[4] Sonzogni A, Previtali G, Seghezzi M, et al. Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations. Liver Int,2020,40(9): 2110-2116.
[5] Wang Y, Liu S, Liu H, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol, 2020,73(4): 807-816.
[6] Chai X, Hu L, Zhang Y, et al. Specific ACE2 expression incholangiocytes may cause liver damage after 2019-nCoV infection. BioRxiv, 2020,3: 931766.
[7] Kumar A, Kumar P, Dungdung A, et al. Pattern of liver function and clinical profile in COVID-19:A cross-sectional study of 91 patients. Diabetes Metab Syndr, 2020,14(6): 1951-1954.
[8] Huang Q, Xie Q, Shi CC, et al. Expression of angiotensin-converting enzyme 2 in CCL4-induced rat liver fibrosis. Int J Mol Med, 2009,23(6): 717-723.
[9] Yang L, Han Y, Nilsson-Payant BE, et al. Ahuman pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell, 2020,27(1): 125-136.
[10] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020,395(10223): 497-506.
[11] Anirvan P, Narain S, Hajizadeh N, et al. Cytokine-induced liver injury in coronavirus disease-2019 (COVID-19):untangling the knots. Eur J Gastroenterol Hepatol, 2021[ahead of print].
[12] Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. BiochemPharmacol, 2009,78(6): 539-552.
[13] Song JC, Wang G, Zhang W, et al. People’ s Liberation Army Professional Committee of Critical Care Medicine, Chinese Society on Thrombosis and Haemostasis. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19. Mil Med Res, 2020,7(1): 19.
[14] Paria BC, Vogel SM,Ahmmed GU, et al. Tumor necrosis factor-alpha-induced TRPC1 expression amplifies store-operated Ca2⁺ influx and endothelial permeability. Am J Physiol Lung Cell Mol Physiol, 2004,287(6): L1303-L1313.
[15] Yang X, Yu Y, Xu J, et al.Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China:a single-centered,retrospective, observational study. Lancet Respir Med, 2020,8(5): 475-481.
[16] Chihara R, Nakamoto H, Arima H, et al. Systemic capillary leak syndrome. Intern Med, 2002, 41(11): 953-956.
[17] Duan CY, Zhang J, Wu HL, et al. Regulatory mechanisms, prophylaxis and treatment of vascular leakage following severe trauma andshock. Mil Med Res, 2017,15(4): 11.
[18] Hiltebrand LB, Krejci V, Banic A, et al. Dynamic study of the distribution of microcirculatory blood flow in multiple splanchnic organs in septic shock. Crit Care Med, 2020,28(9): 3233-3241.
[19] Zhong M, Sun A, Xiao T, et al. A randomized,single-blind,group sequential, active-controlled study to evaluate the clinical efficacy and safety of α-lipoic acid for critically ill patients with coronavirus disease 2019 (COVID-19). MedRxiv, 2020:20066266.
[20] Genctoy G, Altun B, Kiykim AA, et al. TNF alpha-308 genotype and renin-angiotensin system in hemodialysis patients:an effect on inflammatory cytokine levels? Artif Organs, 2005,29(2): 174-178.
[21] Wang R, Alam G, Zagariya A, et al. Apoptosis of lung epithelial cells in response to TNF-alpha requires angiotensin II generation de novo. J Cell Physiol, 2000,185(2): 253-259.
[22] Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited:new roles in inflammation,immunology and aging. EMBO Mol Med, 2010,2(7): 247-257.
[23] Ahmed S, Anirvan P. Reply torheumatologists perspective on coronavirus disease 19:is heparin the dark horse for COVID-19? Clin Rheumatol, 2020,39(7): 2099-2100.
[24] Numaguchi Y, Ishii M, Kubota R, et al. Ablation of angiotensin IV receptor attenuates hypofibrinolysis via PAI-1 downregulation and reduces occlusive arterial thrombosis. ArteriosclerThrombVasc Biol, 2009,29(12): 2102-2108.
[25] Gromotowicz-Poplawska A, Marcinczyk N, Misztal T, et al. Rapid effects of aldosterone on platelets, coagulation,and fibrinolysis lead to experimental thrombosis augmentation. VasculPharmacol, 2019,122-123: 106598.
[26] Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest, 1995,95(3): 995-1001.
[27] Simões E, Silva AC, Miranda AS, et al. Renin angiotensin system in liver diseases:friend or foe? World J Gastroenterol, 2017,23(19): 3396-3406.
[28] Moshage H. Cytokines and the hepatic acute phase response. JPathol, 1997,181(3): 257-266.
[29] Wang D, Yin Y, Yao Y. Advances in sepsis-associated liver dysfunction. Burns Trauma,2014,2(3): 97-105.
[30] Nguyen-Lefebvre AT, Horuzsko A. Kupffer cell metabolism and function. J EnzymolMetab, 2015,1(1): 101.
[31] Spapen H. Liverperfusion in sepsis, septic shock, and multiorgan failure. Anat Rec (Hoboken), 2008,291(6): 714-720.
[32] Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 2020,8(4): 420-422.
[33] Rapkiewicz AV, Mai X, Carsons SE, et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19:a case series. E Clin Med, 2020,24: 100434.
[34] Tian S, Hu W, Niu L, et al. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol, 2020,15(5): 700-704.
[35] Hippensteel JA, LaRiviere WB, Colbert JF, et al.Heparin as a therapy for COVID-19: current evidence and future possibilities. Am J Physiol Lung Cell Mol Physiol, 2020,319(2): L211-L217.
[36] Alhazzani W, Møller MH, Arabi YM, et al.Survivingsepsis campaign:Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med, 2020,48(6): e440-e469.
[37] Shahrbaf MA,Tabary M, Khaheshi I. The right ventricle in COVID-19 patients. Eur Heart J, 2021,42(6): 559-560.
[38] Grillet F, Behr J, Calame P, et al.Acutepulmonary embolism associated with COVID-19 pneumonia detected with pulmonary CT angiography. Radiology, 2020,296(3): E186-E188.
[39] Zhang XJ, Cheng X, Yan ZZ, et al. An ALOX12-12-HETE-GPR31 signaling axis is a key mediator of hepatic ischemia-reperfusion injury. Nat Med, 2018,24(1): 73-83.
[40] Kulkarni AV, Kumar P, Tevethia HV, et al.Systematic review withmeta-analysis:liver manifestations and outcomes in COVID-19. Aliment Pharmacol Ther, 2020,52(4): 584-599.
[41] Yip TC, Lui GC, Wong VW, et al. Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. Gut, 2021,70(4): 733-742.
[42] Hundt MA, Deng Y, Ciarleglio MM, et al.Abnormal liver tests in COVID-19:A retrospective observational cohort study of 1, 827 patients in a major U.S. hospital network. Hepatology, 2020,72(4): 1169-1176.
[43] Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. JGastroenterol Hepatol, 2020,35(5): 744-748.
[44] Wang W, Xu Y, Gao R, et al.Detection of SARS-CoV-2 indifferent types of clinical specimens. JAMA, 2020,323(18): 1843-1844.
[45] Zhang J, Wang S, Xue Y. Fecal specimen diagnosis 2019 novel coronavirus-infected pneumonia. J Med Virol, 2020,92(6): 680-682.
[46] Zhang H, Li HB, Lyu JR, et al. Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection. Int J Infect Dis, 2020, 96: 19-24.
[47] Skok K, Stelzl E, Trauner M, et al. Post-mortem viral dynamics and tropism in COVID-19 patients in correlation with organ damage. Virchows Arch, 2021,478(2): 343-353.
[48] Lamers MM, Beumer J, van der Vaart J, et al.SARS-CoV-2 productively infects human gut enterocytes. Science, 2020,369(6499): 50-54.
[49] Pan L, Mu M, Yang P, et al.Clinicalcharacteristics of COVID-19 patients with digestive symptoms in Hubei,China:A descriptive,cross-sectional,multicenter study. Am J Gastroenterol, 2020,115(5): 766-773.
[50] Amirian ES. Potential fecaltransmission of SARS-CoV-2:Current evidence and implications for public health. Int J Infect Dis, 2020,95: 363-370.
[51] Peiris JS, Chu CM, Cheng VC, et al.Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia:a prospective study. Lancet, 2003, 361(9371): 1767-1772.
[52] Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol, 2011,30(1): 16-34.
[53] Fan Z, Chen L, Li J, et al.Clinicalfeatures of COVID-19-related liver fFunctional abnormality. Clin Gastroenterol Hepatol, 2020,18(7): 1561-1566.
[54] Yang D, Elner SG, Bian ZM, et al.Pro-inflammatory cytokines increase reactive oxygen species through mitochondria and NADPH oxidase in cultured RPE cells. Exp Eye Res, 2007, 85(4): 462-472.

Liver injuries in patients with corona virus disease 2019

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Chen Yejing, Lu Qingping, Gu Shaoying. Comparison of therapeutic efficacy of magnesium isoglycyrrhizinate and compound glycyrrhizin monoamine in treatment of patients with drug-induced liver injury [J]. Journal of Practical Hepatology, 2022, 25(3): 371-374.
[2]	Liu Shangzhi, Zhang Zhiqiang, Li Shengjin. Protective mechanism of Danzhi Xiaoyao powder on hepatic damage in rats with D-galactosamine/lipopolysaccharides-induced acute liver injury [J]. Journal of Practical Hepatology, 2022, 25(2): 179-182.
[3]	Yin Tianquan, Zhao Cheng, Liu Yan. Efficacy of Shenfu injection in treatment of patients with acute liver injury and sepsis [J]. Journal of Practical Hepatology, 2022, 25(2): 295-296.
[4]	Ye Chao, Li Wenyuan, Li Lei, et al. Diagnostic value of percutaneous liver biopsy for patients with liver injury of unknown origin [J]. Journal of Practical Hepatology, 2022, 25(1): 38-41.
[5]	Jiang Xiaoying, Yang Heng, Li Mingwu, et al. Prevention of drug-induced liver injury by orally diammonium glycyrrhetate in naïve patients with pulmonary tuberculosis [J]. Journal of Practical Hepatology, 2022, 25(1): 62-65.
[6]	Xiao Lu, Hu Xian, Cai Yingke, et al. Clinical efficacy of adenosylmethionine and reduced glutathione in treating patients with drug-induced liver injury [J]. Journal of Practical Hepatology, 2022, 25(1): 66-69.
[7]	He Shengfu, Wang Baocan, Fan Jiangao, et al. Clinical features and management of patients with biliary liver injury [J]. Journal of Practical Hepatology, 2022, 25(1): 100-103.
[8]	Li Jingjing, Zou Guizhou. Biliary liver injury: Current state of the art [J]. Journal of Practical Hepatology, 2021, 24(6): 765-768.
[9]	Tang Lei, Zou Guizhou. Management of patients with biliary liver injury caused by surgical diseases [J]. Journal of Practical Hepatology, 2021, 24(6): 769-771.
[10]	Hua Qi, Chen Qi, You Lan. Clinical feature of 142 patients with anti-tuberculosis agents-induced DILI [J]. Journal of Practical Hepatology, 2021, 24(6): 843-846.
[11]	Du Yunfei, Liu Jingrui, Ye Feixiang. Efficacy of N-acetylcysteine and dicyclol combination in the treatment of patients with antituberculous drugs-induced liver injury [J]. Journal of Practical Hepatology, 2021, 24(6): 847-850.
[12]	Guan Haiyan, Yang Wenbin. Clinical features and prognosis of patients with drug-induced liver injury [J]. Journal of Practical Hepatology, 2021, 24(5): 713-716.
[13]	Li Bianli, Xu Lihong. Differential diagnosis of drug-induced liver injury, drug-induced autoimmune hepatitis and autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(4): 460-463.
[14]	Wang Lihui, Zhang Jiaxiang , Liu Shuangping, et al. Alleviation of ConA-induced liver injury by protocatechuic acid in mice [J]. Journal of Practical Hepatology, 2021, 24(3): 323-326.
[15]	Huang Chunyang, Chen Jie, Zhang Xiaodan, et al. Serum ALT/ALP ratio changes and histopathological features of patients with drug-induced liver injury acute hepatocellular type [J]. Journal of Practical Hepatology, 2021, 24(3): 379-382.